Fulcrum Therapeutics to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference
September 5, 2017
Cambridge, Mass., Sept. 5, 2017 – Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies that unlock gene regulation to treat serious genetic diseases, will present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference, to be held September 8, 2017 in New York City.
Robert Gould, Ph.D., Fulcrum’s President and Chief Executive Officer, and Amit Hasija, Chief Business Officer, will give a presentation titled “Restoring Balance in Gene Regulation” at 11:30 a.m. at the Millennium Broadway Hotel & Conference Center.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum’s therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., was launched by Third Rock Ventures in 2016 and named a “Fierce 15” company later that year. For more information, please visit www.fulcrumtx.com.
Ten Bridge Communications